Uday R Khire

This inventor holds 20 USPTO granted patents and 12 published patent applications, plus 1 CIPO patent and 9 EPO patents. Top assignees: Bayer Healthcare LLC, Bayer Pharmaceuticals Corporation, Allomek Therapeutics LLC. Active years: 2003-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Uday R Khire. Retrieved from https://idiyas.com/inventor/uday-r-khire

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 12)

% Patents Active = 20.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 4)

Average Co-Inventor Count = 7.6

ph-index = 12

Forward Citations = 351(Granted Patents)

Location History:

Hamden, CT (US) (2003 - 2014)
Orange, CT (US) (2011 - 2015)

Company Filing History:

Bayer Pharmaceuticals Corporation

patents

1 out of 1

Allomek Therapeutics LLC

Years Active: 2003-2015

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9034861 - MEK inhibitors useful in the treatment of diseases (2015-05-19),

2. 8841330 - Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors (2014-09-23),

3. 8338594 - Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase (2012-12-25),

4. 8153785 - Stabilizing ligands for regulation of protein function (2012-04-10),

5. 8143393 - Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis (2012-03-27),

6. 8129379 - Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis (2012-03-06),

7. 8124630 - ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors (2012-02-28),

8. 7928239 - Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas (2011-04-19),

9. 7897623 - ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors (2011-03-01),

10. 7648986 - Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors (2010-01-19),

11. 7645878 - Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof (2010-01-12),

12. 7625915 - Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas (2009-12-01),

13. 7528255 - Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors (2009-05-05),

14. 7517880 - Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas (2009-04-14),

15. 7371763 - Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas (2008-05-13),

Uday R Khire: Innovator in Pharmaceutical Development

Introduction

Uday R Khire is a prolific inventor based in Orange, CT, with an impressive portfolio of 20 patents. His work focuses on developing innovative pharmaceutical solutions aimed at treating various diseases, showcasing his commitment to advancing medical science.

Latest Patents

Among his latest inventions are two notable patents. The first is related to MEK inhibitors useful in the treatment of diseases. This invention pertains to a compound of Formula (I), where specified components function as described in the patent. These compounds can be utilized in pharmaceutical compositions designed for disease treatment. The second patent revolves around omega-carboxyaryl substituted diphenyl ureas as RAF kinase inhibitors. This invention introduces a new group of aryl ureas aimed at treating RAF-mediated diseases and outlines pharmaceutical compositions suitable for such therapies.

Career Highlights

Throughout his career, Uday has contributed significantly while working with industry leaders such as Bayer Healthcare LLC and Bayer Pharmaceuticals Corporation. His tenure at these companies has enabled him to develop and refine his skills, bringing multiple innovative therapies to fruition.

Collaborations

Uday has collaborated with highly regarded professionals such as Jacques P Dumas and Roger Astbury Smith. These partnerships within the research and pharmaceutical communities have played a critical role in the success of his innovations.

Conclusion

Uday R Khire stands out as a notable inventor in the pharmaceutical field. His inventiveness and collaborative spirit contribute significantly to the development of treatments that enhance patient care and offer hope for many diseases. With his ongoing work, he continues to be a driving force for innovation in healthcare.

Profile summary based on public USPTO records.